Avoiding the Zombie Biopharm trap at Keros $KROS

Episode Summary

Executive Summary: The episode is a bullish but activist-minded thesis on Keros Therapeutics (KROS), framed as a “zombie biotech” trading below net cash after its lead asset, SIBO/Cybo, was halted for safety issues. The host argues KROS should sharply cut costs, stop acting like a standalone drug developer, and instead maximize shareholder value by selling or monetizing assets—especially the Takeda-licensed program—rather than burning cash on uncertain internal development.

Main Topics: Zombie biotech framework (Priority: 5/5): The host explains why biotechs trading below net cash are less about science and more about capital allocation, governance, and whether management will preserve or destroy value. Keros’s post-SIBO reset (Priority: 5/5): Keros’s lead asset was halted after safety issues, collapsing the stock and forcing a reassessment of the company’s remaining assets and cost structure. Takeda license as core value driver (Priority: 5/5): The Takeda deal for KER-050/activin pathway asset is presented as the crown jewel, with upfront cash, milestones, and royalties potentially worth more than the current market cap on a risk-adjusted basis. Skepticism toward 065 and SIBO restart hopes (Priority: 4/5): The host is doubtful that KER-065 has enough value to justify a standalone story and is highly skeptical that the halted SIBO program has a viable path forward. Overhead reduction and capital discipline (Priority: 5/5): A major concern is that Keros has not yet meaningfully cut expenses despite losing its main internal development thesis, leaving it vulnerable to the zombie biotech trap. Shareholder engagement and governance (Priority: 4/5): The episode urges shareholders to communicate with the board and press for either a sale, wind-down, or decisive proof that the remaining pipeline can justify continued spending.

Key Arguments: Biotechs trading below net cash are signaling that management is expected to destroy rather than create value unless proven otherwise. When a pipeline fails, management should not have an automatic right to keep spending the remaining cash; the capital should be returned or redeployed only in a new, properly financed shell. Keros’s Takeda-partnered asset is likely worth substantial risk-adjusted value on its own and may already exceed the company’s market cap. Keros’s remaining internal pipeline, especially KER-065, appears too speculative to justify high overhead and standalone development costs. The company’s overhead was sized for three major programs, but that structure no longer makes sense after SIBO’s collapse and the Takeda licensing of KER-050. Without material cost cuts or clear proof of value creation, Keros risks becoming a classic zombie biotech where insiders keep jobs and bonuses while shareholders absorb the losses. Shareholder engagement is presented as the best way to pressure the board toward value-maximizing action, including selling assets or the company itself.

Data Points: KROS market cap: ~$400 million - Host says the stock is around $10/share and the market cap is roughly $400M at the time of recording. Cash on hand: $560 million - Year-end cash balance reported before the Takeda upfront payment was received. Takeda upfront payment: $200 million - Received in February 2025 after the balance sheet date; increases KROS’s cash position materially. Approximate cash balance after Takeda payment: ~$750 million - Host estimates total cash after the Takeda upfront payment. Cash per share: ~$18/share - Host translates the post-Takeda cash balance into per-share value. 2024 spending: $175 million - Total annual spend while running multiple programs. Personnel expenses: $55 million - Part of 2024 overhead the host says needs major reduction. Professional fees/facilities/supplies: ~$10 million - Additional overhead costs cited as part of the company’s burn. Takeda royalty range: low double digits to high teens - Royalty payments to Keros under the license agreement. Takeda milestone potential: over $1 billion - Potential future milestone payments from the license agreement. Takeda peak sales estimate: $2 billion to $3 billion per year - Takeda’s own investor materials suggest the licensed asset could reach this level of annual revenue. Risk-adjusted NPV of Takeda deal: $400 million to $600 million - Host’s estimate for the combined value of milestones and royalties. SIBO stock reaction: mid/high $60s to ~$18 open - Stock collapse after the trial halt announcement. Sutro insider ownership example: very limited - Used as an example of a classic zombie biotech with weak insider alignment. Phase three success probability for Takeda asset: roughly 50/50 or better - Host’s rough qualitative estimate based on history and Takeda’s diligence.

Pivotal Quotes: "The market is signaling to the company: you are worth less than your cash because we believe every dollar that you spend will be effectively lit on fire." — Andrew Walker: Explaining the zombie biotech thesis and why sub-cash valuations reflect governance concerns, not just scientific risk. "This company needs to be looking at cost cuts and bringing their overhead down materially." — Andrew Walker: Arguing that Keros’s expense base is no longer justified after the SIBO failure and Takeda licensing. "If no one else will develop these drugs, then these drugs should not be developed." — Andrew Walker: Core activist argument that management should not spend shareholder cash on weakly supported programs.

Implications: For investors, the episode frames KROS as a governance and capital-allocation story more than a pure biotech story. Future upside depends on cost cuts, asset monetization, or a sale; otherwise the company risks prolonged value destruction despite its large cash balance.